ALNY News and Press, Alnylam Pharmaceuticals Inc. From 04/03/24

2024-04-03 11:57:45 ET Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward w...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in develo...

– Family Health History Road Trip Program Aims to Inspire Conversations About Health History and Empower Families to Take Control of Their Health – – Genealogist and Health Educator Bernice Bennett Travels Cross-Country to Visit Members of hATTR Amyloidosis Commun...

2024-03-10 00:54:52 ET Summary Alnylam has pushed back the data readout for its HELIOS-B trial from early 2024 to June/July 2024, causing a 10% decline in the stock price. The company has made changes to the study duration, primary endpoint, and secondary endpoints of the trial, r...

2024-03-05 09:57:44 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam's Huge Opportunity Alnylam posts Q4 topline miss;...

– Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added to a Diuretic, Calcium-Channel Blocker or Angiotensin Receptor Blocker – – Zilebesiran Demonstrated an Encouraging Safety and...

2024-02-28 22:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-18 05:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-16 12:30:02 ET Goldman Sachs analyst issues NEUTRAL recommendation for ALNY on February 16, 2024 12:00PM ET. ALNY was trading at $147.8925 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 8 - Buy, ...

A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 66.7% to $3.76 on volume of 298,289,429 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 70.5% to $0.1091 on volume of 172,174,410 shares Sientra Inc. (SIEN) rose 89.9% to $0.342 on volume of ...